Modality
Peptide
MOA
HER2
Target
CD19
Pathway
Tau
HS
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
~Oct 2020
→ ~Jan 2022
Phase 3
Apr 2022
→ Jul 2028
Phase 3Current
NCT03803618
154 pts·HS
2022-04→2028-07·Completed
154 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-022.3y awayPh3 Readout· HS
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
Catalysts
Ph3 Readout
2028-07-02 · 2.3y away
HS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03803618 | Phase 3 | HS | Completed | 154 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 |